NASDAQ:ELEV
Elevation Oncology, Inc.
- Stock
Last Close
3.61
17/05 20:00
Market Cap
197.24M
Beta: -
Volume Today
173.09K
Avg: 819.79K
PE Ratio
−2.16
PFCF: −1.98
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | ||||||
average payables | 3.07M - | 5.66M 84.51% | 6.00M 6.03% | 3.43M 42.81% | ||
average receivables | ||||||
book value per share | -1.40 - | 11.60 930.86% | 2.11 81.83% | 0.00 99.92% | ||
capex per share | -0.00 - | -0.00 - | ||||
capex to depreciation | -4.73 - | -3.19 - | ||||
capex to operating cash flow | 0.01 - | 0.00 - | ||||
capex to revenue | ||||||
cash per share | 4.80 - | 12.06 151.11% | 3.88 67.82% | 0.00 99.94% | ||
days of inventory on hand | ||||||
days payables outstanding | ||||||
days sales outstanding | ||||||
debt to assets | 0.31 - | 0.34 8.21% | ||||
debt to equity | 0.60 - | 0.55 8.41% | ||||
dividend yield | ||||||
earnings yield | -0.09 - | -0.44 380.66% | -4.30 880.61% | -0.00 99.94% | ||
enterprise value | -1.74M - | 109.78M 6,409.21% | -73.25M 166.72% | 5.62M 107.68% | 18.28B 325,075.40% | |
enterprise value over ebitda | -6.36 - | 2.29 135.96% | -0.06 102.60% | -402.26 676,432.26% | ||
ev to operating cash flow | -8.93 - | 2.43 127.20% | -0.07 102.71% | -325.39 494,684.06% | ||
ev to sales | ||||||
free cash flow per share | -0.75 - | -2.49 232.42% | -3.68 47.91% | -0.00 99.96% | ||
free cash flow yield | -0.07 - | -0.41 531.72% | -3.87 837.28% | -0.00 99.92% | ||
graham net net | -1.49 - | 11.33 862.14% | 1.94 82.88% | 0.00 99.93% | ||
graham number | 5.73 - | 26.25 358.42% | 13.92 46.97% | 0.01 99.95% | ||
income quality | 0.71 - | 0.94 32.19% | 0.90 4.51% | 1.23 36.72% | ||
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -197.39 - | |||||
interest debt per share | 1.29 - | 0.00 99.93% | ||||
inventory turnover | ||||||
invested capital | 0.60 - | 0.55 8.41% | ||||
market cap | 189.18M - | 73.04M 61.39% | 22.10M 69.74% | 18.30B 82,690.02% | ||
net current asset value | -5.87M - | -23.20M 295.06% | 140.63M 706.10% | 47.85M 65.98% | 53.68M 12.19% | |
net debt to ebitda | 4.60 - | 4.57 0.71% | 0.17 96.18% | 0.42 141.33% | ||
net income per share | -1.04 - | -2.64 152.93% | -4.09 54.75% | -0.00 99.97% | ||
operating cash flow per share | -0.74 - | -2.49 234.34% | -3.67 47.76% | -0.00 99.96% | ||
payables turnover | ||||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -0.21 - | -0.21 0.43% | -1.01 371.15% | -0.51 49.20% | ||
revenue per share | ||||||
roe | 0.75 - | -0.23 130.44% | -1.94 751.56% | -0.83 57.00% | ||
roic | 0.75 - | -0.23 130.43% | -1.21 429.17% | -0.54 55.58% | ||
sales general and administrative to revenue | ||||||
shareholders equity per share | -1.40 - | 11.60 930.86% | 2.11 81.83% | 0.00 99.92% | ||
stock based compensation to revenue | ||||||
tangible asset value | -5.87M - | -23.08M 293.00% | 140.70M 709.58% | 49.03M 65.15% | 54.81M 11.78% | |
tangible book value per share | -1.40 - | 11.60 930.86% | 2.11 81.83% | 0.00 99.92% | ||
working capital | 1.32M - | 74.00M 5,518.91% | 140.63M 90.04% | 77.28M 45.05% | 83.82M 8.45% |
All numbers in USD (except ratios and percentages)